

Article | 18 February 2026

AI

AI monthly: 3 key questions we have for AI in 2026

With rising technological ambition, continued investment in digital infrastructure and new applications within the healthcare sector, AI enters 2026 at full speed. What lies ahead, and where does the momentum lead? Here are some core questions - with potential answers - which could shape the year



CEO, Jensen Huang says demand for Nvidia products is "sky high"

Can data centre building carry construction spending?

The global data centre boom is [reshaping the construction sector](#) at a pace and scale never seen before. Large-scale projects now routinely exceed \$500 million, and hyperscale campuses can surpass \$20 billion in value. This surge has already made data centres one of the fastest-growing parts of construction pipelines worldwide.

Several constraints are becoming more visible, including vast electrical capacity needs, grid-connection bottlenecks, and possible shortages of transformers and GPUs. Power demand, in particular, is emerging as a key limiting factor, with Goldman Sachs analysts estimating [annual growth rates of 17%](#) through 2028.

Momentum remains geographically uneven, with the US being the unrivalled epicentre of data

centre building. But Europe is also accelerating, with construction pipelines up 43% year-on-year, and capacity continues to cluster around major hubs such as London, Dublin, Amsterdam and Frankfurt. Yet congestion in these centres is increasingly pushing operators and hyperscalers to look elsewhere, redirecting buildouts toward Tier-2 markets such as Warsaw, Helsinki and the Iberian Peninsula.

Against this backdrop, we expect the EU construction sector [to return to growth in 2026](#). Yet, data centre building, while powerful, remains only one segment. High interest rates, labour shortages and persistently elevated material costs still weigh on the broader sector. The current year will show whether data centre momentum can meaningfully counterbalance these headwinds.


When will we see AI revenues surpass investments?

2025 was another year dominated by AI – not just in technology, but across financial markets. According to Morgan Stanley, [AI stocks have driven roughly three-quarters](#) of S&P 500 returns since the launch of ChatGPT. Beyond markets, AI and the multi-trillion-dollar investments around it have become an anchor of economic growth.

Major big-tech companies have recently announced a ramp-up in their capital expenditure plans for 2026 and are now expected to exceed \$630 billion this year. By 2025, investors had already put nearly \$2 trillion into this technology boom. To put that in perspective, the Apollo programme that ultimately brought humankind to the moon is [estimated to have cost around \\$298 billion](#) in today's dollars.

Big tech capital expenditures continue to climb higher in 2026

in \$ billion



Source: Refinitiv, ING Research

For Nvidia CEO Jensen Huang, demand remains “sky high”, and current investment levels appear both appropriate and sustainable. Yet at the same time, free-cash-flow growth is

becoming a challenge for the major hyperscalers, who are increasingly [turning to debt-financed capex](#). This adds vulnerability to the broader financial system should expected returns fail to materialise.

Monetisation is improving, but it's still far from matching the scale of investment. The central uncertainty for 2026 is whether revenues rise fast enough to justify this capital intensity, or whether slowing cash flows and growing reliance on debt signal early limits.

2026 won't deliver the full answers, but it may offer the first clues.

Can AI lead to efficiency gains in healthcare?

The global healthcare industry faces severe labour shortages, with 4.5 billion people lacking access to essential healthcare services and a [projected shortfall](#) of 11 million workers by 2030. As demographic pressure pushes demand higher, AI is increasingly viewed not as a distant vision but as a practical tool to relieve pressure, streamline administrative workloads and free up clinical time.

The rollout of new healthcare-specific chatbots pushes the debate into new territory. A digital "Dr-GPT" could provide initial guidance and help triage symptoms, with early patterns suggesting that younger generations adopt these tools most readily.

At the clinical level, AI is quietly reshaping diagnostic workflows. Systems that analyse X-rays, CT scans, retinal images or ECGs now support earlier detection of cancers, diabetic retinopathy and heart-related conditions — in some cases with accuracy on par with that of human specialists. This does not replace clinical judgement, but it does help surface critical findings sooner and free overstretched staff to focus on complex care.

2026 might reveal the first signals of where AI can meaningfully ease healthcare bottlenecks - and where caution must prevail.

Author

Julian Geib

Junior Economist, Global Trade

julian.geib@ing.de

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies)*. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or

THINK economic and financial analysis

misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit www.ing.com.